Top

Published in:

Open Access 26-08-2022 | Pancreatic Surgery | Mini Review

Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review

Authors: Luca Urso, Alberto Nieri, Ilaria Rambaldi, Angelo Castello, Licia Uccelli, Corrado Cittanti, Stefano Panareo, Irene Gagliardi, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Mirco Bartolomei

Published in: Endocrine | Issue 2/2022

Abstract

In the last 10 years, several literature reports supported radioligand therapy (RLT) in neoadjuvant settings for pancreatic neuroendocrine tumors (PanNETs). Indeed, primary tumor shrinkage has been frequently reported following RLT in unresectable or borderline resectable PanNETs. Moreover, RLT-induced intratumoral modifications facilitate surgery, both on primary tumor and metastasis, having a great impact on progression free survival (PFS), overall survival (OS) and quality of life (QoL). However, prospective controlled investigations are necessary to confirm preliminary data and to define the best RLT scheme and the ideal patient that, in a multidisciplinary approach, should be referred to neoadjuvant RLT.

A.T. Scott, J.R. Howe, Evaluation and management of neuroendocrine tumors of the pancreas. Surg. Clin. North Am. 99, 793–814 (2019). https://doi.org/10.1016/j.suc.2019.04.014CrossRefPubMedPubMedCentral

M. Falconi, B. Eriksson, G. Kaltsas, D.K. Bartsch, J. Capdevila, M. Caplin, B. Kos-Kudla, D. Kwekkeboom, G. Rindi, G. KlÖppel, N. Reed, R. Kianmanesh, R.T. Jensen, ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 153–171 (2016). https://doi.org/10.1159/000443171

A. Sowa-Staszczak, A. Hubalewska-Dydejczyk, M. Tomaszuk, PRRT as neoadjuvant treatment in NET. Recent Results Cancer Res. 479–485 (2013). https://doi.org/10.1007/978-3-642-27994-2_27

J.Y. Kim, S.M. Hong, J.Y. Ro, Recent updates on grading and classification of neuroendocrine tumors. Ann. Diagn. Pathol. 29, 11–16 (2017). https://doi.org/10.1016/j.anndiagpath.2017.04.005CrossRefPubMed

G. Perri, L.R. Prakash, M.H.G. Katz, Pancreatic neuroendocrine tumors. Curr. Opin. Gastroenterol. 35, 468–477 (2019). https://doi.org/10.1097/MOG.0000000000000571CrossRefPubMed

A. Rinke, T.M. Gress, Neuroendocrine cancer, therapeutic strategies in G3 cancers. Digestion 95, 109–114 (2017). https://doi.org/10.1159/000454761CrossRefPubMed

D.L. Chan, R. Thompson, M. Lam, N. Pavlakis, J. Hallet, C. Law, S. Singh, S. Myrehaug, External beam radiotherapy in the treatment of gastroenteropancreatic neuroendocrine tumours: a systematic review. Clin. Oncol. 30, 400–408 (2018). https://doi.org/10.1016/j.clon.2018.03.006CrossRef

R.P. Baum, H.R. Kulkarni, A. Singh, D. Kaemmerer, D. Mueller, V. Prasad, M. Hommann, F.C. Robiller, K. Niepsch, H. Franz, A. Jochems, P. Lambin, D. Hörsch, Results and adverse events of personalized peptide receptor radionuclide therapy with 90 Yttrium and 177 Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget 9, 16932–16950 (2018)

G. Kong, R.J. Hicks, peptide receptor radiotherapy: current approaches and future directions. Curr. Treat. Options Oncol. 20 (2019). https://doi.org/10.1007/s11864-019-0677-7

10.

J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O’Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning, Phase 3 trial of 177 lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017). https://doi.org/10.1056/nejmoa1607427CrossRefPubMedPubMedCentral

11.

J. Ramage, B.G. Naraev, T.R. Halfdanarson, Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Semin. Oncol. 45, 236–248 (2018). https://doi.org/10.1053/j.seminoncol.2018.08.004CrossRefPubMed

12.

T. Brabander, W.A. Van Der Zwan, J.J.M. Teunissen, B.L.R. Kam, R.A. Feelders, W.W. De Herder, C.H.J. Van Eijck, G.J.H. Franssen, E.P. Krenning, D.J. Kwekkeboom, Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23, 4617–4624 (2017). https://doi.org/10.1158/1078-0432.CCR-16-2743

13.

L. Uccelli, A. Boschi, C. Cittanti, P. Martini, S. Panareo, E. Tonini, A. Nieri, L. Urso, M. Caracciolo, L. Lodi, A. Carnevale, M. Giganti, M. Bartolomei, 90Y/177Lu-DOTATOC: from preclinical studies to application in humans. Pharmaceutics 13 (2021). https://doi.org/10.3390/PHARMACEUTICS13091463

14.

G. Paganelli, M. Sansovini, S. Nicolini, I. Grassi, T. Ibrahim, E. Amadori, V. Di Iorio, M. Monti, E. Scarpi, A. Bongiovanni, M. Altini, L. Urso, C. Cittanti, F. Matteucci, S. Severi, ¹⁷⁷Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study, Eur. J. Nucl. Med. Mol. Imaging (2020). https://doi.org/10.1007/s00259-020-04873-0

15.

D. Campana, G. Capurso, S. Partelli, F. Nori, F. Panzuto, D. Tamburrino, G. Cacciari, G. Delle Fave, M. Falconi, P. Tomassetti, Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: Factors associated with response and suggestions for therapeutic sequence. Eur. J. Nucl. Med. Mol. Imaging 40, 1197–1205 (2013). https://doi.org/10.1007/s00259-013-2402-2CrossRefPubMed

16.

S. Partelli, E. Bertani, M. Bartolomei, C. Perali, F. Muffatti, C.M. Grana, M. Schiavo Lena, C. Doglioni, S. Crippa, N. Fazio, G. Zamboni, M. Falconi, Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery 163, 761–767 (2018). https://doi.org/10.1016/j.surg.2017.11.007CrossRefPubMed

17.

M. Albertelli, A. Dotto, C. Di Dato, P. Malandrino, R. Modica, A. Versari, A. Colao, D. Ferone, A. Faggiano, PRRT: identikit of the perfect patient. Rev. Endocr. Metab. Disord. (2020). https://doi.org/10.1007/s11154-020-09581-6

18.

C. Ricci, S. Pusceddu, N. Prinzi, S. Tafuto, T. Ibrahim, A. Filice, M.P. Brizzi, F. Panzuto, S. Baldari, C.M. Grana, D. Campana, M.V. Davì, D. Giuffrida, M.C. Zatelli, S. Partelli, P. Razzore, R. Marconcini, S. Massironi, F. Gelsomino, A. Faggiano, E. Giannetta, E. Bajetta, F. Grimaldi, M. Cives, F. Cirillo, V. Perfetti, F. Corti, C. Ricci, L. Giacomelli, L. Porcu, M. Di Maio, E. Seregni, M. Maccauro, S. Lastoria, A. Bongiovanni, A. Versari, I. Persano, M. Rinzivillo, S.A. Pignata, P.A. Rocca, G. Lamberti, S. Cingarlini, I. Puliafito, M.R. Ambrosio, I. Zanata, A. Bracigliano, S. Severi, F. Spada, V. Andreasi, R. Modica, F. Scalorbi, M. Milione, G. Sabella, J. Coppa, R. Casadei, M. Di Bartolomeo, M. Falconi, F. De Braud, Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw. Open 5, e220290–e220290 (2022). https://doi.org/10.1001/JAMANETWORKOPEN.2022.0290CrossRefPubMedPubMedCentral

19.

E. Giannetta, F. Sesti, R. Modica, E.M. Grossrubatscher, V. Guarnotta, A. Ragni, I. Zanata, A. Colao, A. Faggiano, Case report: unmasking hypercalcemia in patients with neuroendocrine neoplasms. Experience from six Italian referral centers. Front. Endocrinol. (Lausanne). 12, 1 (2021). https://doi.org/10.3389/FENDO.2021.665698CrossRef

20.

G. Puliani, V. Di Vito, T. Feola, F. Sesti, R. Centello, C. Pandozzi, M.G. Tarsitano, M. Verrico, A. Lenzi, A.M. Isidori, E. Giannetta, A. Faggiano, NETest: a systematic review focusing on the prognostic and predictive role. Neuroendocrinology 112, 523–536 (2022). https://doi.org/10.1159/000518873CrossRefPubMed

21.

D. Kaemmerer, V. Prasad, W. Daffner, D. Hörsch, G. Klöppel, M. Hommann, R.P. Baum, Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J. Gastroenterol. 15, 5867–5870 (2009). https://doi.org/10.3748/wjg.15.5867CrossRefPubMedPubMedCentral

22.

S. Ezziddin, H. Lauschke, M. Schaefers, C. Meyer, M. Van Essen, H.J. Biersack, D.J. Kwekkeboom, H. Ahmadzadehfar, Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin. Nucl. Med. 37, 102–104 (2012). https://doi.org/10.1097/RLU.0B013E318238F111CrossRefPubMed

23.

E.I. van Vliet, C.H. van Eijck, R.R. de Krijger, E.J.N. van Dijkum, J.J. Teunissen, B.L. Kam, W.Wde. Herder, R.A. Feelders, B.A. Bonsing, T. Brabander, E.P. Krenning, D.J. Kwekkeboom, Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3] octreotate. J. Nucl. Med. 56, 1647–1653 (2015). https://doi.org/10.2967/JNUMED.115.158899

24.

T.N. da Silva, M.L.F. van Velthuysen, C.H.J. van Eijck, J.J. Teunissen, J. Hofland, W.W. de Herder, Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. Endocrinol. Diabetes Metab. Case Rep. 2018 (2018). https://doi.org/10.1530/edm-18-0015

25.

I. Zanata, M.R. Ambrosio, M.C. Zatelli, Neoadjuvant PRRT for advanced pNEN: an unusual highlander. Endocrine 73, 493–495 (2021). https://doi.org/10.1007/s12020-021-02662-9CrossRefPubMedPubMedCentral

26.

R.V. Parghane, M. Bhandare, V. Chaudhari, V. Ostwal, A. Ramaswamy, S. Talole, S.V. Shrikhande, S. Basu, Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-Dotatate PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 62, 1558–1563 (2021). https://doi.org/10.2967/jnumed.120.258772CrossRefPubMedPubMedCentral

27.

M. Opalińska, A. Sowa-Staszczak, A. Grochowska, H. Olearska, A. Hubalewska-Dydejczyk, Value of peptide receptor radionuclide therapy as neoadjuvant treatment in the management of primary inoperable neuroendocrine tumors. Front. Oncol. 11, 1–8 (2021). https://doi.org/10.3389/fonc.2021.687925CrossRef

28.

T.W. Barber, M.S. Hofman, B.N.J. Thomson, R.J. Hicks, The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur. J. Surg. Oncol. 38, 64–71 (2012). https://doi.org/10.1016/j.ejso.2011.08.129CrossRefPubMed

29.

N.S. Minczeles, C.H.J. van Eijck, M.J. van Gils, M.L.F. van Velthuysen, E.J.M. Nieveen van Dijkum, R.A. Feelders, W.W. de Herder, T. Brabander, J. Hofland. Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. Eur. J. Nucl. Med. Mol. Imaging 1–12 (2022). https://doi.org/10.1007/S00259-022-05734-8/TABLES/5

30.

J. Strosberg, P.L. Kunz, A. Hendifar, J. Yao, D. Bushnell, M.H. Kulke, R.P. Baum, M. Caplin, P. Ruszniewski, E. Delpassand, T. Hobday, C. Verslype, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, G. Paganelli, S. Severi, M. Morse, D.C. Metz, C. Ansquer, F. Courbon, A. Al-Nahhas, E. Baudin, F. Giammarile, D. Taïeb, E. Mittra, E. Wolin, T.M. O’Dorisio, R. Lebtahi, C.M. Deroose, C.M. Grana, L. Bodei, K. Öberg, B.D. Polack, B. He, M.F. Mariani, G. Gericke, P. Santoro, J.L. Erion, L. Ravasi, E. Krenning, Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur. J. Nucl. Med. Mol. Imaging 47, 2372–2382 (2020). https://doi.org/10.1007/s00259-020-04709-xCrossRefPubMedPubMedCentral

31.

M. Schiavo Lena, S. Partelli, P. Castelli, V. Andreasi, C.E. Smart, E. Pisa, M. Bartolomei, E. Bertani, G. Zamboni, M. Falconi, C. Doglioni, Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT). Endocr. Pathol. 31, 119–131 (2020). https://doi.org/10.1007/s12022-020-09623-4

32.

F. Panzuto, S. Puscedddu, A. Faggiano, M. Rinzivillo, N. Brighi, N. Prinzi, F. Riccardi, E. Iannicelli, I. Maggio, D. Femia, S. Tafuto, L. Manuzzi, A. Di Sarno, B. Annibale, F. de Braud, D. Campana, Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: a comparison between pancreatic and gastrointestinal localizations. Pancreatology 19, 1067–1073 (2019). https://doi.org/10.1016/j.pan.2019.09.015CrossRefPubMed

33.

J.R. Howe, N.B. Merchant, C. Conrad, X.M. Keutgen, J. Hallet, J.A. Drebin, R.M. Minter, T.C. Lairmore, J.F. Tseng, H.J. Zeh, S.K. Libutti, G. Singh, J.E. Lee, T.A. Hope, M.K. Kim, Y. Menda, T.R. Halfdanarson, J.A. Chan, R.F. Pommier, The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49, 1–33 (2020). https://doi.org/10.1097/MPA.0000000000001454CrossRefPubMedPubMedCentral

34.

O. Stoeltzing, E. Huber, M. Loss, V. Gross, C. Eilles, J. Mueller-Brand, H.J. Schlitt, Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbeck’s Arch. Surg. 395, 185–192 (2010). https://doi.org/10.1007/s00423-009-0520-xCrossRef

35.

M.H. Squires, P.J. Worth, B. Konda, M.H. Shah, M.E. Dillhoff, S. Abdel-Misih, J.A. Norton, B.C. Visser, M. Dua, T.M. Pawlik, C.R. Schmidt, G. Poultsides, J.M. Cloyd, Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors. Pancreas 355–360 (2020). https://doi.org/10.1097/MPA.0000000000001500

36.

S. Nicolini, L. Bodei, A. Bongiovanni, M. Sansovini, I. Grassi, T. Ibrahim, M. Monti, P. Caroli, A. Sarnelli, D. Diano, V. Di Iorio, C.M. Grana, C. Cittanti, F. Pieri, S. Severi, G. Paganelli, Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging (2021). https://doi.org/10.1007/s00259-021-05236-z/Published

37.

J.R. Strosberg, M.E. Caplin, P.L. Kunz, P.B. Ruszniewski, L. Bodei, A. Hendifar, E. Mittra, E.M. Wolin, J.C. Yao, M.E. Pavel, E. Grande, E. Van Cutsem, E. Seregni, H. Duarte, G. Gericke, A. Bartalotta, M.F. Mariani, A. Demange, S. Mutevelic, E.P. Krenning, 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 1752–1763 (2021). https://doi.org/10.1016/S1470-2045(21)00572-6CrossRefPubMed

38.

K. Sjögreen Gleisner, N. Chouin, P.M. Gabina, F. Cicone, S. Gnesin, C. Stokke, M. Konijnenberg, M. Cremonesi, F.A. Verburg, P. Bernhardt, U. Eberlein, J. Gear, EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur. J. Nucl. Med. Mol. Imaging (2022). https://doi.org/10.1007/s00259-022-05727-7

39.

U. Garske-Román, M. Sandström, K. Fröss Baron, L. Lundin, P. Hellman, S. Welin, S. Johansson, T. Khan, H. Lundqvist, B. Eriksson, A. Sundin, D. Granberg, Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur. J. Nucl. Med. Mol. Imaging 45, 970–988 (2018). https://doi.org/10.1007/s00259-018-3945-zCrossRefPubMedPubMedCentral

40.

L. Bodei, M. Cremonesi, C.M. Grana, M. Chinol, S.M. Baio, S. Severi, G. Paganelli, Yttrium-labelled peptides for therapy of NET, Eur. J. Nucl. Med. Mol. Imaging 39, (2012). https://doi.org/10.1007/s00259-011-2002-y

41.

L. Bodei, M. Cremonesi, G. Paganelli, Yttrium-based therapy for neuroendocrine tumors. PET Clin. 9, 71–82 (2014). https://doi.org/10.1016/j.cpet.2013.10.001CrossRefPubMed

42.

Neoadjuvant PRRT With 177Lu-DOTATATE followed by surgery for resectable PanNET. ClinicalTrials.gov (2022). https://clinicaltrials.gov/ct2/show/NCT04385992 (accessed 20 May 2022)

Title: Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review
Authors: Luca Urso
Alberto Nieri
Ilaria Rambaldi
Angelo Castello
Licia Uccelli
Corrado Cittanti
Stefano Panareo
Irene Gagliardi
Maria Rosaria Ambrosio
Maria Chiara Zatelli
Mirco Bartolomei
Publication date: 26-08-2022
Publisher: Springer US
Keywords: Pancreatic Surgery
Pancreatic Surgery
Radionuclide Therapy
Neuroendocrine Tumor
Published in: Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-03170-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Tumor mutation burden-assisted risk stratification for papillary thyroid cancer

Identification of two potential immune-related biomarkers of Graves’ disease based on integrated bioinformatics analyses

Transcriptome analysis of peripheral blood mononuclear cells in patients with type 1 diabetes mellitus

Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management

COVID-19 patients with altered steroid hormone levels are more likely to have higher disease severity

The COVID-19 outbreak and de-escalation of thyroid cancer diagnosis and treatment

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials